Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $135.6 million.

  • Ultragenyx Pharmaceutical's Change in Acquisitions & Divestments rose 4490.28% to $135.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $481.2 million, marking a year-over-year increase of 1912.62%. This contributed to the annual value of $410.0 million for FY2024, which is 4104.81% down from last year.
  • Ultragenyx Pharmaceutical's Change in Acquisitions & Divestments amounted to $135.6 million in Q3 2025, which was up 4490.28% from $89.4 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Change in Acquisitions & Divestments registered a high of $224.2 million during Q1 2021, and its lowest value of $42.8 million during Q4 2022.
  • Moreover, its 5-year median value for Change in Acquisitions & Divestments was $134.1 million (2021), whereas its average is $138.8 million.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first soared by 16483.17% in 2023, then crashed by 6831.97% in 2024.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Change in Acquisitions & Divestments stood at $134.1 million in 2021, then tumbled by 68.1% to $42.8 million in 2022, then skyrocketed by 164.83% to $113.3 million in 2023, then rose by 5.34% to $119.4 million in 2024, then grew by 13.6% to $135.6 million in 2025.
  • Its Change in Acquisitions & Divestments was $135.6 million in Q3 2025, compared to $89.4 million in Q2 2025 and $136.9 million in Q1 2025.